RE: Mologic25 Feb 2021 19:25
"but just as those who say they are making them don’t actually have that knowledge, neither do you to the contrary TWatcher so don’t pretend otherwise. "
But where does that end, you are suggesting that rampers can say just ANYTHING and unless the company states the opposite, it has to be considered possible ?
You don't need to beleive me, in fact I don't want you to beleive me. simply look at the interim report from 2 weeks ago, as I've done.
" the year-end cash position is expected to be in the region of GBP5.5 million to GBP6.0 million. " I looked at the figure for the close of the previous 1/2, and the cash position @ sept 2020 is £7M.
So entire cash burn for the 6 months to march is estimated by ODX at £1-1.5M, and that includes all the kit they purchased to go from 100k a week capacity to 1M capacity, and the remodelling costs of the factory etc. Revenue from all covid related activities estimated @ £1.5M, that INCLUDES the already known 250K RTC, and some 3rd party work. And that's revenue, the profit on that is a lot less. So it's not like they are forecasting major LFT sales income that can be used to fund production during the 1/2 year.
Now take that ODX estimated cash burn and attempt to mate that to the rampers telling you that ODX has been operating at full capacity each and every month, and will continue to do so to end of the financial period. On an average of 250K a week from Oct to Dec, and 500K a week from Jan to march (I'm way lowballing the actual capacity chart figures), the rampers will have you beleive that ODX will have produced and stored over 9M tests in this financial 1/2 year, with NO impact on cash balance.
Anyone having a cursory glance at ODX's own figures will conclude ODX is not forecasting any manufacturing of tests in there figures. Take that, and add the known fact that ODX has not once stated that they are manufacuring tests (excluding the 250K), or indeed stated or guided production figures, only capacity figures, and the conclusion is blatantly obvious.